OVERVIEW

Novel Options for Cardiovascular Risk Reduction in Patients with Hypertriglyceridemia is organized by Horizon CME.

Activity Launch Date - 10/31/19
Expiration Date - 10/31/20

Target Audience:
The target audience for this CME initiative is primary care providers (IM/FP/GP-MD/DO) and NP/PAs in primary care settings.

Accreditation:
Credit Designation:
Horizon CME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Overview:
This webcast includes an integrated case presentation designed to facilitate learner interaction and active participation. Patient cases illustrate residual CV risk and the need for additional therapy for reducing the risk of cardiovascular events. Learners will review the latest evidence with omega-3 fatty acids and identify patients who are appropriate candidates for treatment to reduce CV risk.

Learning Objectives:
• Assess the role of elevated triglycerides (TG) and their contribution to residual cardiovascular risk in patients with dyslipidemia
• Review the safety and efficacy of omega-3 fatty acids for reducing the risk cardiovascular (CV) events
• Apply the latest evidence to identify dyslipidemia patients who would be appropriate candidates for CV risk reduction with omega-3 fatty acid

Additional details will be posted as soon as information is available.